Caribou Biosciences (CRBU) Free Cash Flow (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Free Cash Flow data on file, last reported at -$27.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 28.55% year-over-year to -$27.0 million in Q1 2026; TTM through Mar 2026 was -$101.6 million, a 28.57% increase from a year earlier, with the FY2025 full-year figure at -$112.4 million, up 21.48% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$27.0 million, down from -$20.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for CRBU reached as high as -$18.1 million in Q2 2023 and fell as low as -$40.0 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$28.2 million across 5 years, with a median of -$27.0 million in 2026.
• Across the five-year window, Free Cash Flow plunged 210.37% in 2022 and surged 48.53% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$21.6 million in 2022, then declined by 9.67% to -$23.7 million in 2023, then sank by 68.99% to -$40.0 million in 2024, then jumped by 48.53% to -$20.6 million in 2025, then slumped by 31.14% to -$27.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$27.0 million in Q1 2026, -$20.6 million in Q4 2025, and -$26.7 million in Q3 2025.